# Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting

Study · id `cardio:ct-nct02690974` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02690974](<https://clinicaltrials.gov/study/NCT02690974>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02690974

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 302 participants.

## Technical summary

Registry record NCT02690974. Allocation not applicable; no masking; primary purpose supportive care. Start 2016-03-08 (actual); primary completion 2017-06-07 (actual). Results posted on 2019-06-07.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose supportive care
- Phase: Phase 4
- Enrolled: 302 participants (enrolled count; ClinicalTrials.gov record NCT02690974, source copy `cardio:ctgov-nct02690974-2019-06-07`, retrieved 2026-10-26)
- Started: 2016-03-08 (actual) (ClinicalTrials.gov record NCT02690974, source copy `cardio:ctgov-nct02690974-2019-06-07`, retrieved 2026-10-26)
- Primary completion: 2017-06-07 (actual) (ClinicalTrials.gov record NCT02690974, source copy `cardio:ctgov-nct02690974-2019-06-07`, retrieved 2026-10-26)
- Completion: 2017-11-29 (actual) (ClinicalTrials.gov record NCT02690974, source copy `cardio:ctgov-nct02690974-2019-06-07`, retrieved 2026-10-26)
- Results first posted: 2019-06-07 (ClinicalTrials.gov record NCT02690974, source copy `cardio:ctgov-nct02690974-2019-06-07`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT02690974, source copy `cardio:ctgov-nct02690974-2019-06-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02690974-2019-06-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
- Acronym: PARASAIL
- Condition: Hearth Failure With Reduced Ejection Fraction (HFrEF)
- Intervention (Drug): LCZ696 (sacubitril/valsartan)
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Sacubitril/valsartan (combination) (`cardio:sacubitril-valsartan`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 61291947ec4c0670836ed6facdb82c45e0c60a155da426d4ebb3dda762888b3d
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
